An increasing number of countries have legalized medical cannabis. There is a broad range in the accessibility of medical cannabis markets in terms of the medical conditions eligible for authorization, the types of cannabis products that can be accessed, and the retail structure for receiving medical cannabis.
There is a need for evidence to understand how medical cannabis policies are meeting the needs of individuals authorized for medical use, and the broader impact on cannabis use and attitudes. For example, how do patterns of medical cannabis use differ from non-medical ‘recreational’ use? How are public perceptions and support for medical cannabis changing in society?
Recent papers
Use of cannabis for mental health in the Canadian territories: A cross sectional study.
Schwartz N, Poon T, Hammond D, Hobin E.
Substance Use and Misuse 2024; Sep 29:1-9. DOI: 10.1080/10826084.2024.2409711. Epub ahead of print.
Canada’s THC Unit: Applications for the Legal Cannabis Market.
Wood S, Gabrys R, Freeman T, Hammond D. Canada’s THC Unit: Applications for the Legal Cannabis Market.
International Journal of Drug Policy 2024; 128: 104457. doi.org/10.1016/j.drugpo.2024.104457.
Bhatia D, Sakai J, Reddy S, Mikulich S, Hammond D.
Obstetrics & Gynecology 2024; In press.
Social norms for cannabis use following non-medical legalization in Canada.
Winfield-Ward L, Hammond D.
American Journal of Preventive Medicine 2023; S0749-3797(23)00513-5.
Rup J, Freeman T, Perlman CP, Hammond D.
Substance Use & Misuse 2022; 57(5):719-729.
Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada.
Leung J, Chan G, Stjepanović D, Chung JYC, Hall W, Hammond D.
Psychopharmacology 2022; 239(5): 1509-1519.
Rup J, Freeman T, Perlman C, Hammond D.
Addictive Behaviors; 2021; 121:106991.
Mental health and medical cannabis use among youth and young adults in Canada.
Wadsworth E, Leos-Toro C, Hammond D.
Substance Use and Misuse 2019: 55(4):582-589.